New biomarker predicts improved outcomes with dose-dense chemotherapy in ER-positive breast cancer
A new biomarker study provides novel insights into how dose-dense chemotherapy can improve survival for some patients with estrogen receptor (ER)-positive breast cancer. In the study, researchers analyzed 12-year follow-up data from the Phase III CALGB 9741 trial, which included 1,973 patients with node-positive, early-stage breast cancer. The results showed that dose-dense chemotherapy, given every two weeks instead of the standard three-week schedule, improved disease-free survival by 20% and overall survival by 15%. Using a biomarker test developed at...











